Merit Medical Systems (NASDAQ:MMSI) Given New $97.00 Price Target at Bank of America
Merit Medical Systems (NASDAQ:MMSI) Given New $97.00 Price Target at Bank of America
Merit Medical Systems (NASDAQ:MMSI), a leading supplier of medical instruments, saw its valuation climb after Bank of America upgraded its target price to $97.00 from $92.00 on Thursday morning, according to a Benzinga report. The brokerage maintains a neutral rating on the stock, but the upward tweak signals growing confidence in the company's earnings outlook.
đź“Š Key Facts At A Glance
- →Merit Medical Systems (NASDAQ:MMSI) Given New
- →00 and citing stronger demand for its endoscopic and imaging systems
- →Merit Medical Systems’ Q1 2026 financials show revenue of
- →00 target signals a positive outlook for Merit Medical Systems, reflecting confidence in its product pipeline and financial performance
What Happened
Bank of America's research team released a new note on Thursday, raising the price target by $5.00 and citing stronger demand for its endoscopic and imaging systems. The firm also highlighted recent product launches that are expected to boost revenue streams. In the same quarter, other analysts, including Citigroup, reiterated an “outperform” stance on MMSI, underscoring a consensus that the company's fundamentals are solid.
Earlier this week, Merit Medical Systems reported a 12% year‑over‑year increase in net sales, driven largely by its new robotic-assisted surgical devices. The company’s earnings per share (EPS) for Q1 2026 surpassed estimates by 8%, helping to justify the revised target.
Bank of America's upgrade comes amid a broader market rally in the medical technology sector, where companies like Medtronic and Stryker have also seen their valuations rise.
Key Details
Bank of America’s updated target of $97.00 reflects a projected 18% upside from the current market price of $84.00, as of the day’s close. The brokerage’s neutral rating indicates that it believes the stock will perform in line with its peers, while still recognizing potential upside.
Merit Medical Systems’ Q1 2026 financials show revenue of $1.18 billion, up 12% YoY, with a gross margin of 36.4%. The company’s operating income rose to $120 million, a 15% increase, while net income reached $88 million, a 10% gain over the same period last year.
In addition, the firm announced a strategic partnership with a leading university to develop next‑generation endoscopic imaging, expected to launch in Q3 2026. This collaboration could open new revenue avenues and enhance Merit’s competitive edge.
Background
Founded in 1993, Merit Medical Systems has grown into a global provider of minimally invasive medical devices, with a focus on endoscopy, imaging, and surgical instruments. The company operates in over 50 countries and employs more than 2,000 staff worldwide.
Merit’s core products include the EndoWrist™ robotic platform, the FlexiScope™ endoscopic systems, and a range of imaging solutions that have garnered regulatory approvals in the U.S., EU, and Japan. The firm’s revenue mix is diversified across surgical, diagnostic, and interventional markets, reducing reliance on any single segment.
Why It Matters
The price target upgrade reflects confidence in Merit’s ability to capitalize on the expanding minimally invasive surgery market, projected to grow at a CAGR of 8.5% through 2028. Analysts note that the company’s strong product pipeline and strategic partnerships position it well to capture market share from competitors.
From an investor perspective, the neutral rating coupled with an upward target suggests a balanced view: while the stock is not seen as a “buy” at current levels, the potential for upside remains significant. The upgrade may attract new institutional investors looking for exposure to the medical technology space without overpaying.
What Happens Next
In the coming weeks, Merit Medical Systems is expected to release its Q2 earnings report, which will provide further insight into the performance of its new robotic systems. Market watchers will closely monitor whether the company meets its revenue and margin targets, as this could influence further analyst revisions.
Bank of America and other research firms may adjust their ratings based on the Q2 results and any additional product announcements. Should the company continue to exceed expectations, we could see a shift from neutral to “outperform,” potentially driving the stock higher.
In summary, Bank of America's $97.00 target signals a positive outlook for Merit Medical Systems, reflecting confidence in its product pipeline and financial performance. Investors will likely monitor the company’s upcoming earnings and partnership developments to gauge whether the stock can deliver on its new valuation.
đź“– See Also
đź“š Sources & Attribution
- âś“ Defense World